Is APGE or APRE more undervalued in 2026?

CirclFi compares Apogee Therapeutics, Inc. (APGE) and Aprea Therapeutics, Inc. (APRE) using 13 institutional-grade valuation models. APGE has a Quality of Company score of 4.2/10 while APRE scores 4.5/10.

Which is a better buy — APGE or APRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do APGE and APRE valuations compare?

APGE at $77.82 and APRE at $0.93 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

APGE vs APRE Valuation Comparison 2026 — Intrinsic Value Analysis

APGE

Biotechnology

Apogee Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$77.82

Last close

Models

10/13

Active

APRE

Biotechnology

Aprea Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$0.93

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	APGE Fair Value	APGE Upside	APRE Fair Value	APRE Upside
Bayesian DCF	Intrinsic	$26.30	-66.2%	$2.30	+147.6%
Earnings Power Value	Intrinsic	$37.75	-55.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$5.69	-92.7%	$0.80	-14.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for APGE vs APRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

APGE vs APRE — Which Stock Is More Undervalued?

APRE scores higher with a 4.5/10 quality rating vs APGE's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Apogee Therapeutics, Inc. (APGE) and Aprea Therapeutics, Inc. (APRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

APGE currently trades at $77.82 with a QOC of 4.2/10, while APRE trades at $0.93 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).